��������

James (“Jim”) Collins has more than 20 years of experience in Global BioPharma Executive leadership at Eli Lilly and Sanofi. Mr. Collins dedicated his time in BioPharma to creating innovative delivery devices that help people take their medicine as conveniently as possible, including the Trulicity pen.

Using human-centered design principles, Mr. Collins and his teams partnered with world-class design, development, and manufacturing companies to ideate, develop, and launch multiple market-leading delivery device technologies. Mr. Collins’ key BioPharma drug delivery accomplishments include the creation at Lilly of market leading insulin KwikPen Platform, the Trulicity pen Platform, the Talz pen Platform, the Savvio Pen, the Forteo Pen, and many others. At Sanofi, multiple devices were developed for Toujeo, Soliqua, Praluent, Kevzara, and Dupixent including the development and launch of a number of first-to-market delivery systems, including the first 2mL PFS safety system with BD, and the first-to-market 2mL autoinjector in partnership with SHL.

Mr. Collins received his Bachelor’s degree in Naval Architecture from the U.S. Naval Academy and his M.B.A. from Georgia State University.